EAM
CLDX icon

Eventide Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Quarter Market Value Status Shares Shares
Change %
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$27.6M Sell
1,356,186
-2,398,607
-64% -$48.8M 0.48% 75
2025
Q1
$68.2M Buy
3,754,793
+1,533
+0% +$27.8K 1.36% 17
2024
Q4
$94.8M Buy
3,753,260
+421,255
+13% +$10.6M 1.73% 8
2024
Q3
$113M Buy
3,332,005
+4,873
+0.1% +$166K 1.95% 9
2024
Q2
$123M Buy
3,327,132
+208,045
+7% +$7.7M 2.11% 9
2024
Q1
$131M Sell
3,119,087
-510,926
-14% -$21.4M 2.05% 8
2023
Q4
$144M Buy
3,630,013
+2,030,013
+127% +$80.5M 2.35% 5
2023
Q3
$44M Buy
1,600,000
+222,260
+16% +$6.12M 0.79% 44
2023
Q2
$46.7M Hold
1,377,740
0.79% 43
2023
Q1
$49.6M Sell
1,377,740
-85,310
-6% -$3.07M 0.91% 35
2022
Q4
$65.2M Sell
1,463,050
-328,750
-18% -$14.7M 1.29% 27
2022
Q3
$50.4M Buy
1,791,800
+346,100
+24% +$9.73M 0.99% 37
2022
Q2
$39M Hold
1,445,700
0.83% 44
2022
Q1
$49.2M Buy
1,445,700
+206,800
+17% +$7.04M 0.77% 45
2021
Q4
$47.9M Buy
1,238,900
+110,900
+10% +$4.29M 0.61% 54
2021
Q3
$60.9M Sell
1,128,000
-980,908
-47% -$53M 0.8% 40
2021
Q2
$70.5M Buy
2,108,908
+46,475
+2% +$1.55M 0.95% 39
2021
Q1
$42.5M Buy
2,062,433
+225,325
+12% +$4.64M 0.63% 60
2020
Q4
$32.2M Buy
1,837,108
+1,330,929
+263% +$23.3M 0.49% 65
2020
Q3
$7.51M Buy
506,179
+42,844
+9% +$635K 0.15% 104
2020
Q2
$6.02M Buy
+463,335
New +$6.02M 0.13% 100
2016
Q1
Sell
-420,500
Closed -$6.59M 140
2015
Q4
$6.59M Buy
420,500
+191,700
+84% +$3.01M 0.33% 73
2015
Q3
$2.41M Sell
228,800
-59,900
-21% -$631K 0.14% 95
2015
Q2
$7.28M Hold
288,700
0.39% 62
2015
Q1
$8.05M Hold
288,700
0.61% 60
2014
Q4
$5.27M Hold
288,700
0.58% 61
2014
Q3
$3.74M Hold
288,700
0.52% 62
2014
Q2
$4.71M Hold
288,700
0.64% 59
2014
Q1
$5.1M Buy
288,700
+31,700
+12% +$560K 0.79% 53
2013
Q4
$6.22M Buy
+257,000
New +$6.22M 1.92% 26